KOSDAQBiotech & Pharma214150

Classys

₩22,200▼ 1.11%2026-11-18 close
Market Cap
₩1.4T
Turnover
₩8.5B
Volume
380K
Shares out.
65.2M
PER
14.0×
PBR
2.8×
EPS
₩1,700
Dividend Yield
4.20%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas expansion continues as Q3 2026 profit drops sharply

Classys grew revenue and operating profit every year from 2022 through 2025, but Q3 2026 operating profit and net profit attributable to controlling shareholders fell sharply from a year earlier, so the trend after Q3 is the key point to watch.

  1. 1

    Revenue in 2025 was KRW 336.8 billion, up 38.6% from a year earlier, and operating profit was KRW 170.6 billion, up 39.3%. It was the largest year in the 2022 to 2025 period.

  2. 2

    Q3 2026 operating profit was KRW 27 billion, down 28.2% from a year earlier, and net profit attributable to controlling shareholders was KRW 6.28 billion, down 81.0%. Press reports attributed the decline to overseas direct-subsidiary transition costs and a product changeover in Korea.

  3. 3

    According to the company's announcement, cumulative revenue for January to September 2026 was KRW 275.7 billion, up 13% year on year, while cumulative operating profit was KRW 108.1 billion, down 9.4%.

  4. 4

    Regional revenue in 2025 was 29% Asia, 21% Europe and Middle East, and 17% the Americas, making overseas markets a core pillar of the business.

  5. 5

    The 2026 revenue outlook presented with the Q1 results was KRW 470 to 510 billion. Against nine-month cumulative revenue of KRW 275.7 billion, reaching the low end would require KRW 194.3 billion in Q4 alone.

02

Business structure

Classys makes and sells energy-based aesthetic medical devices using radiofrequency (RF) and high-intensity focused ultrasound (HIFU), and it also sells the consumables needed after each device is installed.

Its main devices are the HIFU device Ultraformer (sold in Korea as Shrink) and the monopolar RF device Volnewmer (sold in the US as Everesse). As of the March 2025 Daishin Securities report, the revenue mix was 46% devices, 45% consumables and 9% other.

According to Hana Securities, device revenue in Q4 2025 reached KRW 50.5 billion, or 54% of total, helped by new product effects. The company said its consumables share rose to about 53% and gross margin approached 80%. By region in 2025, Asia was 29%, Europe and the Middle East 21%, and the Americas 17%.

Ieru was consolidated from Q4 2024, and Hana Securities put Ieru's 2025 revenue at KRW 60 billion, or 18% of the total. In March 2026, the acquisition of Brazilian distributor MedSystems was completed, giving the company direct operations in major South American markets.

Hugel and PharmaResearch also operate in aesthetic products within the same sector, but their business structures differ from a device-and-consumables model, so direct comparison is limited.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩83B₩37.6B45.3%
2025Q4₩93.4B₩51.2B54.8%
2026Q1₩87.2B₩37.2B42.7%
2026Q2₩105.5B₩43.9B41.6%
2026Q3₩83B₩27B32.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩141.8B₩68.9B₩75.4B48.6%32.8%44.4%
2023₩180.1B₩89.6B₩74.2B49.8%26.2%32.4%
2024₩242.9B₩122.4B₩97.9B50.4%21.6%34.4%
2025₩336.8B₩170.6B₩131.9B50.7%23.9%27.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 141.8 billion in 2022 to KRW 180.1 billion in 2023 (up 27.0%), KRW 242.9 billion in 2024 (up 34.9%), and KRW 336.8 billion in 2025 (up 38.6%), with three consecutive years of growth from 2023 through 2025.

Operating profit increased from KRW 68.9 billion in 2022 to KRW 170.6 billion in 2025, and 2025 was the largest year in the 2022 to 2025 range. The operating margin rose every year, from 48.6% in 2022 to 49.8%, 50.4% and 50.7% in 2025.

Net profit attributable to controlling shareholders fell 1.5% to KRW 74.2 billion in 2023, then rose to KRW 97.9 billion in 2024 and KRW 131.9 billion in 2025, two consecutive years of growth. Net income including non-controlling interests was KRW 132 billion in 2025.

The debt-to-equity ratio fell from 44.4% in 2022 to 27.7% in 2025, and operating cash flow rose from KRW 54.8 billion to KRW 163.9 billion.

Quarterly revenue went from KRW 83 billion in Q3 2025 to KRW 93.4 billion in Q4 2025, when operating profit peaked at KRW 51.2 billion; Q4 also included a one-off reversal of bad-debt provisions linked to Brazil of about KRW 4.4 billion.

Q1 2026 revenue was KRW 87.2 billion with operating profit of KRW 37.2 billion, a period that reflected one-off acquisition fees along with heavy event and advertising spending.

Q2 2026 revenue was KRW 105.5 billion, and the company said it passed KRW 100 billion in quarterly revenue for the first time, with operating profit of KRW 43.9 billion.

Q3 2026 revenue was KRW 83 billion, flat year on year, but operating profit fell to KRW 27 billion, down 28.2%, and net profit attributable to controlling shareholders declined for three straight quarters to KRW 6.28 billion. Net profit attributable to controlling shareholders for the last four quarters totaled KRW 110.9 billion.

05

Industry analysis

The aesthetic device market works in a sequence in which devices are installed first and consumables sales follow, so both installed base and treatment demand matter.

The company said its cumulative installed base reached 46,000 units as of March 2026 and that its market share rose across North America, Europe and Asia. It also said cumulative global unit sales reached 50,000 as of October 2026.

Hana Securities noted that Volnewmer and Ultraformer MPT are penetrating the European market quickly, and identified Europe as the region where the largest revenue gains were expected.

In the US, the microneedle RF device Quadessy was slated for launch in early Q2 2026, and Volnewmer, sold there as Everesse, was described as generating more than KRW 10 billion in annual revenue. Hana Securities indicated that China was not included in the 2026 business plan figures and would be added from 2027.

Reports attributed weaker domestic sales in Q3 2026 to a changeover of a key product in Korea. Among aesthetic peers, Hugel and PharmaResearch operate in the same sector, while Classys differs by pairing HIFU and RF devices with a consumables model.

06

Outlook

The company presented its 2026 revenue outlook at KRW 470 to 510 billion with its Q1 results, while a February Hana Securities report summarized the guidance at KRW 490 billion. Nine-month cumulative revenue reached KRW 275.7 billion, up 13% year on year.

Reaching the low end of KRW 470 billion would require KRW 194.3 billion in Q4, more than double Q4 2025 revenue of KRW 93.4 billion.

Hana Securities expected the Brazilian direct subsidiary's revenue and profit to be booked at the parent level as the structure matures in 2026, and expected results from the Japanese direct subsidiary to become visible through its hospital network.

The company has presented China entry as part of its strategy to accelerate growth in 2027. Whether Quadessy sales after its US launch hold up, and whether Volnewmer's US revenue level is sustained, are points to check in upcoming quarterly results.

How quickly overseas direct-subsidiary transition costs, cited as a factor in the Q3 profit decline, fade after Q4 will also show whether the operating margin can recover.

07

Valuation

PER
14.0×
PBR
2.8×
ROE
20.7%
EPS
₩1,700
BPS
₩8,487
Dividend per share
₩1,000

The current share price sits in a range where the premium to book value is large. Market capitalization is more than twice the controlling shareholders' equity at the end of 2025, which means the share price leans more on earnings growth than on net asset value.

In analyst tables from the past, the PER for 2023 and 2024 was in the low-to-mid 30s. Operating profit in 2025 more than doubled from 2022, so earnings scale expanded substantially.

However, net profit attributable to controlling shareholders for the last four quarters, at KRW 110.9 billion, is below the KRW 131.9 billion recorded for 2025, and the sharp Q3 decline makes whether the earnings trend has turned the central question for valuation.

The debt-to-equity ratio of 27.7% at end-2025 indicates a relatively light debt burden. How the valuation reads depends on whether earnings resume growth and how the overseas revenue share develops.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

A widening overseas revenue base

Regional revenue in 2025 was 29% Asia, 21% Europe and Middle East, and 17% the Americas, without heavy concentration in one region. Hana Securities said Volnewmer and Ultraformer MPT are penetrating Europe quickly. The US launch of Quadessy and the China approval process are positioned as the next overseas growth drivers.

Consumables-driven earnings structure

The company said its consumables share rose to about 53% and gross margin approached 80%. The operating margin was 50.7% in 2025, higher than 48.6% in 2022. Paid consumables orders from installed devices serve as a stabilizing factor for earnings.

A relatively light balance sheet

The debt-to-equity ratio fell from 44.4% in 2022 to 27.7% in 2025. Operating cash flow rose from KRW 54.8 billion to KRW 163.9 billion. This financial capacity provides a base for absorbing overseas direct-subsidiary and acquisition costs.

09

Bear factors

Sharp profit decline in Q3

In Q3 2026, both operating profit and net profit attributable to controlling shareholders fell from a year earlier, with the decline in net profit larger than that in operating profit. Net profit attributable to controlling shareholders declined for three consecutive quarters from Q1 through Q3 2026. Press reports cited overseas direct-subsidiary transition costs and a domestic product changeover as causes.

Pressure to reach the guidance

Nine-month cumulative revenue is KRW 275.7 billion, and reaching the KRW 470 billion low end would require KRW 194.3 billion in Q4. That compares with Q4 2025 revenue of KRW 93.4 billion, so a large step-up would be needed. Q3 revenue held flat year on year, which makes Q4 acceleration a point to watch.

Product concentration and domestic weakness

Main devices are concentrated in Ultraformer (Shrink) and Volnewmer. Press reports said domestic sales weakened in Q3 2026 due to a changeover of a key product. Demand shifts in a specific product could affect both device and consumables revenue at the same time.

10

Risk factors

Regulatory and approval timing

The China opportunity depends on the Volnewmer approval process and local regulatory preparations. Hana Securities noted China was not included in the 2026 business plan figures and would be added from 2027. Approval delays could push back the timing of overseas growth.

Overseas subsidiary transition and M&A integration

The Brazil MedSystems acquisition was delayed beyond its original schedule, which pushed back the consolidation of its revenue. Direct-subsidiary transition carries costs, which were cited as a factor in the Q3 operating profit decline. If post-acquisition integration keeps costs high, margin recovery could be slower.

Earnings swings from one-off items

Q4 2025 operating profit included a one-off reversal of bad-debt provisions linked to Brazil of about KRW 4.4 billion. In Q1 2026, one-off acquisition fees overlapped with heavy event and advertising spending.

Quarterly results can swing significantly with such items, so the line-item detail in periodic reports should be checked together.

11

What to watch next

  1. Around February 2027

    Q4 2026 results announcement. Check how close Q4 revenue came to the KRW 194.3 billion needed, against nine-month cumulative revenue of KRW 275.7 billion, to reach the low end of guidance.

  2. By end-March 2027

    Filing of the 2026 annual business report. Check whether the operating margin holds from 50.7% in 2025 and how overseas direct-subsidiary transition costs appear in annual figures.

  3. Around May 2027

    Q1 2027 results announcement. Check whether the operating profit decline since Q3 2026 has stopped, and how the domestic product changeover and Quadessy sales in the US show up in results.

  4. During 2027 (timing not yet set)

    Whether Volnewmer receives approval in China and when local revenue begins to be booked. Check whether China sales, which Hana Securities said would be added from 2027, actually appear in reported figures.

12

Overall view

Classys grew revenue from KRW 141.8 billion in 2022 to KRW 336.8 billion in 2025 and operating profit from KRW 68.9 billion to KRW 170.6 billion, with the operating margin rising from 48.6% to 50.7%. Net profit attributable to controlling shareholders also rose in both 2024 and 2025 after its 2023 low.

However, Q3 2026 operating profit of KRW 27 billion and net profit attributable to controlling shareholders of KRW 6.28 billion fell sharply from a year earlier, and quarterly net profit has declined for three consecutive quarters.

Regional revenue is spread across Asia, Europe and the Middle East, and the Americas, and new products and China entry are being prepared, which shows a widening growth base.

Still, reaching the low end of the 2026 guidance requires a large Q4 revenue step-up, and how much of the direct-subsidiary transition cost and product changeover affects margins remains uncertain.

This report summarizes DART-filed results, company announcements and brokerage analyses as facts, and the next checkpoints are the Q4 2026 results announcement and the 2026 annual business report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. hanaw.com
  2. truefriend.com
  3. myasset.com
  4. moneytoring.ai
  5. rapportian.com
  6. ebn.co.kr
  7. m.pharmstock.co.kr
  8. dailyinvest.kr
  9. needinfo.co.kr
  10. hanaw.com
  11. money2.daishin.co.kr
  12. srtimes.kr
  13. m.news.nate.com
  14. classys.co.kr

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis